EMC China Lab

Evaluation of Chronic Toxicity and Carcinogenicity of Medical Devices

Views :
Update time : 2025-03-01

With the implementation of ISO 10993-1:2018, most devices that have prolonged contact with the human body (>30 days) now require an evaluation of chronic toxicity and carcinogenicity as part of their biological risk assessment. In Table A.1 (iso 10993-1:2018), these biological endpoints are marked with an "E", indicating that they must be evaluated during risk assessment. This evaluation can be conducted using existing data, additional endpoint-specific tests, or a justified rationale explaining why additional data are unnecessary. The inclusion of these biological evaluation endpoints has also drawn regulatory attention, with review feedback requiring further refinement of chronic toxicity and carcinogenicity assessments based on Table A.1.

 

Evaluation of Chronic Toxicity and Carcinogenicity of Medical Devices(图1)


Chronic Toxicity Test (Project Duration: ~8–14 months)

Chronic toxicity is a systemic toxicity study conducted by repeated or continuous exposure to the test sample throughout a significant portion of the animal's lifespan to observe any adverse effects. Animals should be continuously exposed for 6–12 months. When using rodents (rats, mice) for single-dose group studies, each group should include at least 30 animals (15 per sex). The evaluation of repeated exposure studies is based on body weight, clinical observations, hematology, clinical biochemistry, gross pathology, histopathology, and other test indicators.

 

Carcinogenicity Test (Project Duration: ~32–34 months)

The purpose of the carcinogenicity test is to assess tumor development in test animals during or after exposure to different doses of the test material through appropriate routes, covering major life stages of the animals.

 

- If an extract-based test is used, a standalone carcinogenicity study can be conducted according to OECD TG 451, or a combined chronic toxicity and carcinogenicity study can be conducted following OECD TG 453 to comprehensively evaluate both biological endpoints while considering the possibility of solid-state carcinogenicity.

- When evaluating the carcinogenicity of a medical device using a single animal species, the selection and justification should follow ISO 10993-2.

- For rodents, each group should include at least 50 animals per sex, with the study typically lasting 24 months to cover most of the animal’s lifespan.

 

Evaluation criteria include body weight, clinical observations, tumor formation and progression, hematology, gross pathology, histopathology, and other test indicators. Although transgenic animals can be used for carcinogenicity tests, their application in medical device evaluations has not yet been established.

 

Alternatives to Animal Testing for Chronic Toxicity and Carcinogenicity Evaluations

Both chronic toxicity and carcinogenicity studies involve long-term animal testing, posing significant financial and time challenges for product development. So, is animal testing always necessary for evaluating these biological endpoints?

 

According to iso 10993-18 (Material Chemical Characterization) and ISO 10993-17 (Toxicological Risk Assessment), toxicological evaluations based on material characterization can be used for assessing systemic toxicity endpoints, including:

 

- Systemic toxicity (acute, subacute, subchronic, and chronic toxicity)

- Genotoxicity

- Reproductive toxicity

- Carcinogenicity

 

Therefore, when determining whether to conduct chronic toxicity and carcinogenicity studies, it is essential to first consider the intended use and classification of the device to identify whether these biological endpoints require evaluation.

 

Manufacturers should leverage existing product information as much as possible, including raw materials, manufacturing processes, preclinical and clinical data (if available). When additional studies are necessary to support risk assessment, a tiered approach is recommended:

 

1. Prioritize chemical and physical characterization

2. Perform in vitro screening tests

3. Review characterization and in vitro test results before proceeding with animal testing

4. Justify the necessity of long-term animal studies

 

By following this approach, the biological risk assessment can be conducted in a scientifically rational and efficient manner.


Email:hello@jjrlab.com


Leave Your Message


Write your message here and send it to us


Related News
Read More >>
Introduction to RE, CE and ESD in EMC Testing Introduction to RE, CE and ESD in EMC Testing
04 .03.2026
JJR Lab : RE, CE and ESD ensure EMC compliance by controlling emissions and verifying immunity, so d...
EMC Testing: EMI / EMS / RE / CE / CS / ESD EMC Testing: EMI / EMS / RE / CE / CS / ESD
04 .03.2026
EMC ensures devices neither cause nor suffer interference. EMI (CE, RE) measures emissions, while EM...
Important: Latest Notice on SASO IEC 62680 Important: Latest Notice on SASO IEC 62680
04 .03.2026
SASO delays IEC 62680 enforcement to May 1, 2026; non-compliant devices lose COC eligibility. JJR LA...
What is BS EN 1388-2 Certification Testing What is BS EN 1388-2 Certification Testing
04 .03.2026
EN 1388-2 strictly limits lead/cadmium in ceramic tableware; JJR LAB tests heavy metal migration usi...
How to get a BS EN 1388-1 Compliance Report? How to get a BS EN 1388-1 Compliance Report?
04 .03.2026
Ceramic tableware must meet BS EN 1388-1 limits for lead/cadmium; tested via EN 1388-2 under simulat...
What is BS EN 1388-1 Certification Testing? What is BS EN 1388-1 Certification Testing?
04 .03.2026
BS EN 1388-1 tests ceramic foodware for lead and cadmium migration, ensuring full CE compliance and ...
What is FCC ID Used For What is FCC ID Used For
04 .02.2026
FCC ID ensures wireless devices meet US RF, SAR, and EMC safety standards; JJR Lab provides professi...
AS/NZS 4417.2:2020 Amd 1:2026 Australia and New Ze AS/NZS 4417.2:2020 Amd 1:2026 Australia and New Ze
04 .02.2026
AS/NZS 4417.2:2020 Amd 1:2026 strengthens AU/NZ electrical safety by adding categories, tightening c...

Leave Your Message